Objective To investigate the effect of sorafenib and / or thalidomide on angiogenesis in chick chorioallantoic membrane( CAM).Methods White eggs incubated for 7 days were used to establish a CAM model. The model eggs were randomly divided blank control group,sorafenib group,thalidomide group,and sorafenib / thalidomide group. After treatment,each egg was incubated for another 2 days.The CAM samples were collected and fixed to take their pictures under a microscope,and the vascular coverage of each sample was calculated.Comparison between these groups was made by analysis of variance,and comparison between each two groups was made by SNK- q test.Results The thalidomide group or sorafenib group had significantly lower vascular coverage than the blank control group( 30. 2% ± 2. 9%or 26. 5% ± 2. 1% vs 38. 3% ± 2. 7%,P < 0. 05). The sorafenib / thalidomide group had significantly lower vascular coverage than the thalidomide group or sorafenib group( 12. 6% ± 1. 5% vs 30. 2% ± 2. 9% or 26. 5% ± 2. 1%,P < 0. 05). Conclusion Both sorafenib and thalidomide have a good anti- angiogenic effect on CAM,but a combination of the two drugs shows better efficacy.
[1]FORNER A,LLOVET JM,BRUIX J.Hepatocellular careinoma[J].Lancet,2012,379(9822):1245-1255.
|
[2]FOLKMAN J.Angiogenesis in cancer,vascular,rheumatoid and other disrease[J].Nat Med,1995,1(1):27-31.
|
[3]DUAN ZX,XIE LQ.Role of the vascular endothelial growth factor signaling pathway in tumor growth and angiogenesis[J].World Chin J Dig,2010,18(27):2894-2900.(in Chinese)段泽星,谢立群.VEGF在肿瘤生长和血管生成中的作用[J].世界华人消化杂志,2010,18(27):2894-2900.
|
[4]WANG D,LUO L,CHEN W,et al.Significance of the vascular endothelial growth factor and the macrophage migration inhibitory factor in the progression of hepatocellular carcinoma[J].Oncol Rep,2014,31(3):1199-1204.
|
[5]CHOW NH,HSU PI,LIN XZ,et al.Expression of vascular endothelial growth factor in normal liver and hepatocellular carcinoma:an immunohistochemical study[J].Hum Pathol,1997,28(6):698-703.
|
[6]PARK YN,KIM YB,YANG KM,et al.Increased expression of vascular endothelialgrowth factor and angiogenesis in the early stage of multistep hepatocarcinogenesis[J].Arch Pathol Lab Med,2000,124(7):1061-1065.
|
[7]CHEN C,YU DC,TENG LS.Development of anti-tumor drugs targeting VEGF/VEGFR:a progress[J].Chin J Cancer Biother,2007,14(3):291-295,300.(in Chinese).陈川,俞德超,滕理送.以VEGF/VEGFR为靶点的抗肿瘤药物的研究进展[J].中国肿瘤生物治疗杂志,2007,14(3):291-295,300.
|
[8]CHENG BX,FANG X,ZHU CL,et al.Altered expression levels of miRNAs in serum of patients with hepatocellular carcinoma in the treatment of sorafenib[J].China Med Herald 2014,11(9):41-44.(in Chinese)成炳祥,方煊,朱承良,等.索拉非尼对肝癌患者血清中肿瘤相关miRNAs的影响[J].中国医药导报,2014,11(9):41-44.
|
[9]PERSONENI N,RIMASSA L,PRESSIANI T,et al.Molecular determinants of outcome in sorafenib treated patients with hepatocellular carcinoma[J].J Cancer Res Clin Oncol,2013,139(7):1179-1187.
|
[10]ZHU AX.Molecularly targeted therapy for advanced hepatocellular carcinoma in 2012:current status and future perspectives[J].Semin Oncol,2012,39(4):493-502.
|
[11]PAN JQ,LU GP,YU ZJ.Thalidomide on anti-tumor research[J].Chin J Cancer Prev Treat,2012,19(7):552-555.(in Chinese)潘骥群,鲁光平,于志坚.沙利度胺抗肿瘤的研究进展[J].中华肿瘤防治杂志,2012,19(7):552-555.
|
[12]ALEXANIAN R,WEBER D.Thalidomide for resist and relapsing myeloma[J].Semin Hematol,2000,37(1):22-25.
|
[13]DAHUT WL,GULLEY JL,ARLEN PM,et al.Randomizedphase II trial of docetaxel plus thalidomide in and rogenindependent prostate cance[J].J Clin Oncol,2004,22(13):2532-2539.
|
[14]HUNG KC,HSIEH PM,YANG KL,et al.Effect of thalidomide on the expression of vascular endothelial growth factor in a rat model of liver regeneration[J].Oncol Lett,2013,5(3):852-856.
|
[15]WAINBERG ZA,DRAKAKI A.The importance of optimal drug sequencing in metastatic colorectal cancer:biological rationales for the observed survival benefit conferred by firstline treatment with EGFR inhibitors[J].Expert Opin Biol Ther,2015,15(8):1205-1220.
|
[16]ABOU-ALFA GK,JOHNSON P,KNOX JJ,et al.Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma:a randomized trial[J].JAMA,2010,304(19):2154-2160.
|
[17]SHI P.Effect of thalidomide-Gemox combination on VEGF level in patients with advanced liver cancer[J].China Prac Med,2014,9(34):134-135.(in Chinese)时沛.沙利度胺联合Gemox方案对中晚期肝癌患者VEGF水平的影响[J].中国实用医药,2014,9(34):134-135.
|